Non-Small Cell Lung Cancer Coverage from Every Angle
Advertisement
Advertisement

ASCO20: Tiragolumab Plus Atezolizumab for PD-L1–Selected NSCLC

By: Julia Fiederlein
Posted: Tuesday, June 23, 2020

According to Delvys Rodriguez-Abreu, MD, of the Hospital Universitario Insular de Gran Canaria, Spain, and a host of multinational colleagues, treatment with the anti–T-cell immunoreceptor with Ig and ITIM domains (TIGIT) antibody tiragolumab plus atezolizumab appears to improve progression-free survival and objective response rates in patients with PD-L1–selected non–small cell lung cancer (NSCLC). The findings of the phase II CITYSCAPE trial were presented during the ASCO20 Virtual Scientific Program (Abstract 9503).

“The immunomodulatory receptor TIGIT is a novel inhibitory immune checkpoint present on activated T cells and NK cells in multiple cancers, including NSCLC,” the investigators commented. “We conducted this…trial to confirm the efficacy and safety of tiragolumab plus atezolizumab compared [with] placebo plus atezolizumab [as first-line therapy for] NSCLC.”

A total of 135 patients with chemotherapy-naive PD-L1–positive locally advanced or metastatic NSCLC without EGFR or ALK alterations participated in the study. To be enrolled, patients were required to have an Eastern Cooperative Oncology Group performance status score between 0 and 1. They were randomly assigned to receive atezolizumab therapy with either tiragolumab (n = 67) or a placebo (n = 68) in a 1:1 allocation ratio.

Based upon the primary analyses, the experimental treatment appeared to improve progression-free survival and objective response rates. The median progression-free survival times in the experimental and placebo arms approximately 6 months after the primary analyses were 5.6 and 3.9 months, respectively. The objective response rate was 37.3% in the experimental arm and 20.6% in the placebo arm.

Treatment-emergent adverse events were reported in 80.6% of the experimental arm and 72% of the placebo arm. The investigators reported treatment-emergent adverse events of grade 3 or higher in 14.9% versus 19.1% of patients in the experimental and placebo arms, respectively. Approximately 6 months after the primary analyses, the two arms continued to exhibit tolerable safety profiles.

Disclosure: For full disclosures of the study authors, visit coi.asco.org.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.